Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
09 06 2022
09 06 2022
Historique:
received:
14
02
2022
accepted:
24
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.
Identifiants
pubmed: 35680872
doi: 10.1038/s41467-022-30884-6
pii: 10.1038/s41467-022-30884-6
pmc: PMC9184525
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3203Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
JAMA Intern Med. 2022 Feb 1;182(2):179-184
pubmed: 34846533
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156-1162
pubmed: 34437524
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
N Engl J Med. 2021 Oct 7;385(15):1431-1433
pubmed: 34496195
Clin Infect Dis. 2022 Feb 11;74(3):472-478
pubmed: 33999127
N Engl J Med. 2021 Dec 23;385(26):2413-2420
pubmed: 34879190
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Int J Cardiol. 2011 Nov 3;152(3):345-9
pubmed: 20826019
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Ann Intern Med. 2022 May;175(5):674-681
pubmed: 35157493
Nat Med. 2021 Dec;27(12):2108-2110
pubmed: 34728830
Eur J Epidemiol. 2003;18(12):1143-6
pubmed: 14758871
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770